References
- Balogh J , VictorD3rd, AshamEHet al. Hepatocellular carcinoma: a review. J. Hepatocell. Carcinoma3, 41–53 (2016).
- Ferlay J , SoerjomataramI, ErvikMet al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (2013).
- Forner A , LlovetJM, BruixJ. Hepatocellular carcinoma. Lancet379(9822), 1245–1255 (2012).
- Mittal S , El-SeragH. Epidemiology of hepatocellular carcinoma: consider the population. J. Clin. Gastroenterol.47(Suppl.), S2–S6 (2013).
- Omata M , ChengAL, KokudoNet al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int.11(4), 317–370 (2017).
- Bruix J , ShermanM. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology53(3), 1020–1022 (2011).
- Llovet JM , BruC, BruixJ. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis.19(3), 329–338 (1999).
- Cancer Research UK. Let’s beat cancer sooner: survival. www.cancerresearchuk.org/about-cancer/liver-cancer/survival.
- Forner A , GilabertM, BruixJ, RaoulJL. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol.11(9), 525–535 (2014).
- Tsochatzis EA , FatourouE, O’beirneJ, MeyerT, BurroughsAK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J. Gastroenterol.20(12), 3069–3077 (2014).
- Llovet JM , RicciS, MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4), 378–390 (2008).
- Trojan J , WaidmannO. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J. Hepatocell. Carcinoma3, 31–36 (2016).
- Chow PHW , GandhiM, Asia-Pacific Hepatocellular Carcinoma Trials Group. Phase III multicentre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: the SIRveNIB study. J. Clin. Oncol.35(Suppl.), A4002 (2017).
- Vilgrain V , PereiraH, AssenatEet al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase 3 trial. Lancet Oncol.18(12), 1624–1636 (2017).
- Kelley K , ClarkB, BrownV, SitziaJ. Good practice in the conduct and reporting of survey research. Int. J. Qual. Health Care15(3), 261–266 (2003).
- HCC patient voices survey . http://eprints.lse.ac.uk/84143.
- Word Art . www.wordart.com.
- Kumar A . Current practices in management of hepatocellular carcinoma in India: results of an online survey. J. Clin. Exp. Hepatol.4(Suppl. 3), S140–S146 (2014).
- Kudo M , IzumiN, IchidaTet al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol. Res.46(5), 372–390 (2016).
- Soubrane O , GoumardC, LaurentAet al. Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients. HPB (Oxford)16(4), 357–365 (2014).
- Foley KL , FarmerDF, PetronisVMet al. A qualitative exploration of the cancer experience among long-term survivors: comparisons by cancer type, ethnicity, gender, and age. Psychooncology15(3), 248–258 (2006).
- Hawkins NA , PollackLA, LeadbetterSet al. Informational needs of patients and perceived adequacy of information available before and after treatment of cancer. J. Psychosoc. Oncol.26(2), 1–16 (2008).
- Fallowfield L , FordS, LewisS. No news is not good news: information preferences of patients with cancer. Psychooncology4(3), 197–202 (1995).
- Bowling A . Measuring Health: A Review Of Quality Of Life Measurement Scales. Open University Press, Buckingham, UK (1991).
- Bowling A . Measuring Disease: A Review Of Disease-Specific Quality Of Life Measurement Scales (2nd Edition). Open University Press, Buckingham, UK (1995).
- Fan SY , EiserC, HoMC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin. Gastroenterol. Hepatol.8(7), 559–564e551–510 (2010).
- Kondo Y , YoshidaH, TateishiRet al. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J. Gastroenterol. Hepatol.22(2), 197–203 (2007).
- Steel JL , ChopraK, OlekMC, CarrBI. Health-related quality of life: hepatocellular carcinoma, chronic liver disease, and the general population. Qual. Life Res.16(2), 203–215 (2007).